REAL-WORLD CHARACTERISTICS OF THE FIRST USERS OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS IN ISRAEL

Clara Weil  1     Gabriel Chodick  2     Adva Yarden  3     Karolina Minda  4     Javaria Mona Khalid  5     Varda Shalev  6    
1 Maccabi Healthcare Services, Epidemiology, Tel Aviv, Israel
2 Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel
3 Takeda Pharmaceuticals Israel, Tel Aviv, Israel
4 Takeda Pharmaceuticals International AG, Zurich, Switzerland
5 Takeda Development Centre Europe Ltd, Global Outcomes Research, London, United Kingdom
6 Tel Aviv

Conference
UEG Week 2016

Citation
United European Gastroenterology Journal; 2016: 2 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at office@ueg.eu

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing